API | sumanirole

sumanirole Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Sumanirole (PNU-95,666) is a highly selective D2 receptor full agonist, the first of its kind to be discovered. It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action. ^Wikipedia

Chemistry

SMILES: CN[C@H]1CN2C(=O)Nc3cccc(C1)c23
InChIKey: RKZSNTNMEFVBDT-MRVPVSSYSA-N
Mol. Mass: 203.25
ALogP: 0.47 Partition coefficient
ChEMBL Molecule:
sumanirole

More Chemistry

Pharmacology

Mechanism of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5,6-dihydro-5-(methylamino)-4h-imidazo(4,5,1ij)-quinolin-2(1h)-one (z)-2-butenedioate | pnu-95666 | pnu-95666e | sumanirole | u 95666e | u-95666e

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Parkinson Disease (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue